PMC7337603_01
Densitometry results before (A) November 30, 2017 and after (B) November 20, 2018 treatment for 1 year with ospemifene 60 mg + calcium 600 mg + vitamin D3 1000 IU daily.
dic-2020-3-3-g001.jpg
PMC7337603_01_dic-2020-3-3-g001.jpg
f1-dic-2020-3-3
T-scores were -2.5 for the lumbar spine (no change) and -1.4 for the hip (improvement) (Figure 1).
PMC7337603_02
Lateral radiograph of the lumbar spine showing the absence of morphometric vertebral fractures.
dic-2020-3-3-g002.jpg
PMC7337603_02_dic-2020-3-3-g002.jpg
f2-dic-2020-3-3
She had no personal or family history of osteoporotic fractures; no other risk factors and no morphometric fractures were observed on radiological assessment of the spine (Figure 2).
Vulvar inspection of the patient.
dic-2020-3-3-g003.jpg
PMC7337603_02_dic-2020-3-3-g003.jpg
f3-dic-2020-3-3
At presentation in April 2017, a gynecological examination (Pap smear) showed atrophy (Figure 3).
PMC7337603_03
Densitometry results in December 2017, before the start of ospemifene treatment: (A) lumbar spine; (B) hip.
dic-2020-3-3-g004b.jpg
PMC7337603_03_dic-2020-3-3-g004b.jpg
f4-dic-2020-3-3
T-scores were -0.9 for the lumbar spine and -0.3 for the hip (Figure 4).
Densitometry results in December 2018, 1 year after the start of ospemifene treatment: A) lumbar spine; B) hip.
dic-2020-3-3-g005b.jpg
PMC7337603_03_dic-2020-3-3-g005b.jpg
f5-dic-2020-3-3
T-scores were 0.3 for the lumbar spine and -0.2 for the hip (Figure 5).